Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nexturn Bio
Seoul, South Korea
- Ownership
- Private
- Development stage
- Other
01
Overview
Nexturn Bio is a Korean biotech subsidiary of Nexturn Bioscience that is building a pipeline of miRNA-based therapeutics through a strategic 50% stake in RosVivo Therapeutics; lead asset RSVI-301 for diabetes and additional programs for COVID-19 and metabolic/gastrointestinal diseases have shown promising pre-clinical animal data but had not yet entered clinical trials at the time of the latest public disclosures.[2][3][4]
- Therapeutic areas
- EndocrinologyInfectious DiseasesGastroenterology
- Modalities
- RNA therapy
- Industry
- Biotech
02
Partnerships
RosVivo Therapeutics[2][3][4]
Beyond the preview
Go deeper on Nexturn Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nexturn Bio.